Clinical, quality of life, patient adherence, and safety outcomes of short-course (12 Weeks) treatment with cyclosporine in patients with severe psoriasis (the practice study)

Sandra Swimberghe, Pierre Dominique Ghislain, Evis Daci, Katrien Allewaert, Kris Denhaerynck, Christine Hermans, Christy Pacheco, Stefaan Vancayzeele, Karen MacDonald, Ivo L Abraham

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Apart from clinical outcomes, the "realworld" outcomes of intermittent short-course cyclosporine treatment remain poorly documented. Objective: To evaluate various outcomes of short-course cyclosporine treatment for severe psoriasis; and to describe dermatologists' use of the Rule of Tens. Methods: A 12-week pharmacoepidemiological study; 112 evaluable patients recruited by 43 dermatologists. Results: The mean initial cyclosporine dose was 2.88±0.74 mg/kg/day. At 12 weeks, 64.3% of patients were continued beyond the study period at mean dose of 2.51±0.91 mg/kg/day. Percent body surface affected, Psoriasis Area Severity Index score, and patient and physician rating of psoriasis severity decreased significantly, while quality of life (QoL) improved significantly. Median patient satisfaction at 12 weeks was 85 (0∼100 scale). Patient-reported non-adherence was 43.9% and 56.1%, respectively at both the time points (p=0.18). In modeling on logarithmized outcomes variables, living along was consistently the single most important (negative) determinant of therapeutic and patient outcomes. Safety and tolerance parameters were similar to the ones reported in the literature. Only 7.3% of physicians correctly identified the measures included in the Rule of Tens and the Rule's criterion for inferring severe psoriasis. Conclusion: With adequate monitoring and patient adherence, cyclosporine treatment reduces the severity of severe psoriasis, improves QoL, and is appropriately tolerated; leading to high patient satisfaction. Social support is a key determinant of therapeutic and patient outcomes and patients living along may require clinical attention. The relevance of the Rule of Tens was not evident.

Original languageEnglish (US)
Pages (from-to)28-35
Number of pages8
JournalAnnals of Dermatology
Volume25
Issue number1
DOIs
StatePublished - Feb 2013

Fingerprint

Patient Safety
Patient Compliance
Psoriasis
Cyclosporine
Quality of Life
Patient Satisfaction
Therapeutics
Physicians
compound A 12
Social Support
Safety

Keywords

  • Cyclosporine
  • Pharmacoepidemiology
  • Psoriasis
  • Treatment outcome

ASJC Scopus subject areas

  • Dermatology

Cite this

Clinical, quality of life, patient adherence, and safety outcomes of short-course (12 Weeks) treatment with cyclosporine in patients with severe psoriasis (the practice study). / Swimberghe, Sandra; Ghislain, Pierre Dominique; Daci, Evis; Allewaert, Katrien; Denhaerynck, Kris; Hermans, Christine; Pacheco, Christy; Vancayzeele, Stefaan; MacDonald, Karen; Abraham, Ivo L.

In: Annals of Dermatology, Vol. 25, No. 1, 02.2013, p. 28-35.

Research output: Contribution to journalArticle

Swimberghe, Sandra ; Ghislain, Pierre Dominique ; Daci, Evis ; Allewaert, Katrien ; Denhaerynck, Kris ; Hermans, Christine ; Pacheco, Christy ; Vancayzeele, Stefaan ; MacDonald, Karen ; Abraham, Ivo L. / Clinical, quality of life, patient adherence, and safety outcomes of short-course (12 Weeks) treatment with cyclosporine in patients with severe psoriasis (the practice study). In: Annals of Dermatology. 2013 ; Vol. 25, No. 1. pp. 28-35.
@article{2d1869ffb029421ca6027c8f0fc82a93,
title = "Clinical, quality of life, patient adherence, and safety outcomes of short-course (12 Weeks) treatment with cyclosporine in patients with severe psoriasis (the practice study)",
abstract = "Apart from clinical outcomes, the {"}realworld{"} outcomes of intermittent short-course cyclosporine treatment remain poorly documented. Objective: To evaluate various outcomes of short-course cyclosporine treatment for severe psoriasis; and to describe dermatologists' use of the Rule of Tens. Methods: A 12-week pharmacoepidemiological study; 112 evaluable patients recruited by 43 dermatologists. Results: The mean initial cyclosporine dose was 2.88±0.74 mg/kg/day. At 12 weeks, 64.3{\%} of patients were continued beyond the study period at mean dose of 2.51±0.91 mg/kg/day. Percent body surface affected, Psoriasis Area Severity Index score, and patient and physician rating of psoriasis severity decreased significantly, while quality of life (QoL) improved significantly. Median patient satisfaction at 12 weeks was 85 (0∼100 scale). Patient-reported non-adherence was 43.9{\%} and 56.1{\%}, respectively at both the time points (p=0.18). In modeling on logarithmized outcomes variables, living along was consistently the single most important (negative) determinant of therapeutic and patient outcomes. Safety and tolerance parameters were similar to the ones reported in the literature. Only 7.3{\%} of physicians correctly identified the measures included in the Rule of Tens and the Rule's criterion for inferring severe psoriasis. Conclusion: With adequate monitoring and patient adherence, cyclosporine treatment reduces the severity of severe psoriasis, improves QoL, and is appropriately tolerated; leading to high patient satisfaction. Social support is a key determinant of therapeutic and patient outcomes and patients living along may require clinical attention. The relevance of the Rule of Tens was not evident.",
keywords = "Cyclosporine, Pharmacoepidemiology, Psoriasis, Treatment outcome",
author = "Sandra Swimberghe and Ghislain, {Pierre Dominique} and Evis Daci and Katrien Allewaert and Kris Denhaerynck and Christine Hermans and Christy Pacheco and Stefaan Vancayzeele and Karen MacDonald and Abraham, {Ivo L}",
year = "2013",
month = "2",
doi = "10.5021/ad.2013.25.1.28",
language = "English (US)",
volume = "25",
pages = "28--35",
journal = "Annals of Dermatology",
issn = "1013-9087",
publisher = "Korean Dermatological Association",
number = "1",

}

TY - JOUR

T1 - Clinical, quality of life, patient adherence, and safety outcomes of short-course (12 Weeks) treatment with cyclosporine in patients with severe psoriasis (the practice study)

AU - Swimberghe, Sandra

AU - Ghislain, Pierre Dominique

AU - Daci, Evis

AU - Allewaert, Katrien

AU - Denhaerynck, Kris

AU - Hermans, Christine

AU - Pacheco, Christy

AU - Vancayzeele, Stefaan

AU - MacDonald, Karen

AU - Abraham, Ivo L

PY - 2013/2

Y1 - 2013/2

N2 - Apart from clinical outcomes, the "realworld" outcomes of intermittent short-course cyclosporine treatment remain poorly documented. Objective: To evaluate various outcomes of short-course cyclosporine treatment for severe psoriasis; and to describe dermatologists' use of the Rule of Tens. Methods: A 12-week pharmacoepidemiological study; 112 evaluable patients recruited by 43 dermatologists. Results: The mean initial cyclosporine dose was 2.88±0.74 mg/kg/day. At 12 weeks, 64.3% of patients were continued beyond the study period at mean dose of 2.51±0.91 mg/kg/day. Percent body surface affected, Psoriasis Area Severity Index score, and patient and physician rating of psoriasis severity decreased significantly, while quality of life (QoL) improved significantly. Median patient satisfaction at 12 weeks was 85 (0∼100 scale). Patient-reported non-adherence was 43.9% and 56.1%, respectively at both the time points (p=0.18). In modeling on logarithmized outcomes variables, living along was consistently the single most important (negative) determinant of therapeutic and patient outcomes. Safety and tolerance parameters were similar to the ones reported in the literature. Only 7.3% of physicians correctly identified the measures included in the Rule of Tens and the Rule's criterion for inferring severe psoriasis. Conclusion: With adequate monitoring and patient adherence, cyclosporine treatment reduces the severity of severe psoriasis, improves QoL, and is appropriately tolerated; leading to high patient satisfaction. Social support is a key determinant of therapeutic and patient outcomes and patients living along may require clinical attention. The relevance of the Rule of Tens was not evident.

AB - Apart from clinical outcomes, the "realworld" outcomes of intermittent short-course cyclosporine treatment remain poorly documented. Objective: To evaluate various outcomes of short-course cyclosporine treatment for severe psoriasis; and to describe dermatologists' use of the Rule of Tens. Methods: A 12-week pharmacoepidemiological study; 112 evaluable patients recruited by 43 dermatologists. Results: The mean initial cyclosporine dose was 2.88±0.74 mg/kg/day. At 12 weeks, 64.3% of patients were continued beyond the study period at mean dose of 2.51±0.91 mg/kg/day. Percent body surface affected, Psoriasis Area Severity Index score, and patient and physician rating of psoriasis severity decreased significantly, while quality of life (QoL) improved significantly. Median patient satisfaction at 12 weeks was 85 (0∼100 scale). Patient-reported non-adherence was 43.9% and 56.1%, respectively at both the time points (p=0.18). In modeling on logarithmized outcomes variables, living along was consistently the single most important (negative) determinant of therapeutic and patient outcomes. Safety and tolerance parameters were similar to the ones reported in the literature. Only 7.3% of physicians correctly identified the measures included in the Rule of Tens and the Rule's criterion for inferring severe psoriasis. Conclusion: With adequate monitoring and patient adherence, cyclosporine treatment reduces the severity of severe psoriasis, improves QoL, and is appropriately tolerated; leading to high patient satisfaction. Social support is a key determinant of therapeutic and patient outcomes and patients living along may require clinical attention. The relevance of the Rule of Tens was not evident.

KW - Cyclosporine

KW - Pharmacoepidemiology

KW - Psoriasis

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=84877279905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877279905&partnerID=8YFLogxK

U2 - 10.5021/ad.2013.25.1.28

DO - 10.5021/ad.2013.25.1.28

M3 - Article

C2 - 23467644

AN - SCOPUS:84877279905

VL - 25

SP - 28

EP - 35

JO - Annals of Dermatology

JF - Annals of Dermatology

SN - 1013-9087

IS - 1

ER -